Of @ prespecified secondary outcomes , @ were analyzed , including asthma exacerbation ; of those @ , the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control ( @ g/d -LSB- @ % CI , @-@ @ g/d -RSB- in the vitamin D@ group vs @ g/d -LSB- @ % CI , @-@ @ g/d -RSB- in the placebo group ; difference of @ g/d -LSB- @ % CI , @-@ @ g/d -RSB- ) .